![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/8/88/Vosaroxin.svg/640px-Vosaroxin.svg.png&w=640&q=50)
Vosaroxin
Chemical compound / From Wikipedia, the free encyclopedia
Vosaroxin (AG-7352, SPC-595, SNS 595, voreloxin) is a topoisomerase II inhibitor causing site-selective DNA damage. It is under phase III clinical trial investigation for acute myelogenous leukemia (AML) and ovarian cancer sponsored by Sunesis.[1]
Quick Facts Names, Identifiers ...
![]() | |
Names | |
---|---|
Preferred IUPAC name
7-[(3S,4S)-3-Methoxy-4-(methylamino)pyrrolidin-1-yl]-4-oxo-1-(1,3-thiazol-2-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid | |
Other names
Voreloxin | |
Identifiers | |
3D model (JSmol) |
|
ChEBI | |
ChemSpider | |
PubChem CID |
|
UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
Properties | |
C18H19N5O4S | |
Molar mass | 401.44 g·mol−1 |
Density | 1.5±0.1 g/cm3 |
Pharmacology | |
L01XX53 (WHO) | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Close